|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
This head-to-head comparison suggests that WFA<sup>+</sup> -M2BP is superior to M2BP for distinguishing liver fibrosis stages in NAFLD patients.
|
29274190 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2 Binding Protein Glycosylation isomer (M2BPGi) is a novel serological glyco-biomarker for staging liver fibrosis.
|
28486931 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.
|
27349650 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis.
|
26396155 |
2016 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2-binding protein glycosylation isomer (M2BPGi), a novel serum marker for liver fibrosis, was seldom studied in chronic hepatitis B (CHB).
|
29915243 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mac-2 binding protein glycosylation isomer (M2BPGi) is a reliable and non-invasive marker for assessing liver fibrosis.
|
31339606 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA<sup>+</sup> -M2BP) is a novel serum marker of hepatic fibrosis in adults with chronic hepatitis C. However, it remains unclear whether serum WFA<sup>+</sup> -M2BP levels are associated with the progression of liver histology in primary sclerosing cholangitis (PSC).
|
29168311 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
We compared histological liver fibrosis and serum ACE levels and evaluated the predictive potential to diagnose significant liver fibrosis by comparison with several biochemical marker-based indexes such as the aspartate aminotransferase (AST)-to-platelet ratio index (APRI), the fibrosis index based on four factors (FIB-4), the Mac-2 binding protein glycosylation isomer (M2BPGi) level and the number of platelets (Plt).
|
29085215 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
We explored the usefulness of four novel biomarkers, enhanced liver fibrosis (ELF), glycosylation isomer of Mac-2 binding protein (M2BPGi), galectin-3, and soluble suppression of tumorigenicity 2 (sST2), in association with liver fibrosis.
|
29611383 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
WFA-M2BP can support a diagnosis of liver fibrosis with similar diagnostic efficacy to other biomarkers, and predicted liver fibrosis stage ≥2 among patients with chronic hepatitis B.
|
29611385 |
2018 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sensitivity and specificity of WFA<sup>+</sup> -M2BP for assessing liver fibrosis staging in chronic liver diseases with broad etiologies were determined.
|
28406534 |
2017 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, the patients in the higher value group had significantly worse prognosis after NASH diagnosis CONCLUSION: AKR1B10 is a useful serum biomarker for advanced liver fibrosis in NASH and, combined with serum WFA(+)-M2BP, can predict HCC development, gastroesophageal varix formation, and poor prognosis.
|
30707282 |
2019 |
|
LGALS3BP
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis.
|
31392502 |
2019 |